Cholestanol derivative for combined use

Abstract

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

1 - 8 . (canceled) 
     
     
         9 . A cancer chemotherapy, comprising administering, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       wherein G represents GlcNAc- or a cyclodextrin inclusion compound thereof and an anti-cancer agent, to a patient in need thereof. 
     
     
         10 . The cancer chemotherapy according to  claim 9 , wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously, or separately and intermittently. 
     
     
         11 . The cancer chemotherapy according to  claim 9 , wherein the drug containing a cholestanol derivative is a liposomal formulation. 
     
     
         12 . The method for cancer chemotherapy according to  claim 9 , wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil. 
     
     
         13 . The method for cancer chemotherapy according to  claim 12 , wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cisplatin, Oxaliplatin, Cyclophosphamide, and Irinotecan. 
     
     
         14 . The method for cancer chemotherapy according to  claim 9 , wherein the anticancer agent is Cisplatin.